121 related articles for article (PubMed ID: 7490726)
1. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
Brooks CD; Stewart AO; Basha A; Bhatia P; Ratajczyk JD; Martin JG; Craig RA; Kolasa T; Bouska JB; Lanni C
J Med Chem; 1995 Nov; 38(24):4768-75. PubMed ID: 7490726
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
Stewart AO; Bhatia PA; Martin JG; Summers JB; Rodriques KE; Martin MB; Holms JH; Moore JL; Craig RA; Kolasa T; Ratajczyk JD; Mazdiyasni H; Kerdesky FA; DeNinno SL; Maki RG; Bouska JB; Young PR; Lanni C; Bell RL; Carter GW; Brooks CD
J Med Chem; 1997 Jun; 40(13):1955-68. PubMed ID: 9207936
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773.
Carter GW; Bell RL; Marsh K; Lanni C; Awni WM; Bouska J; Stewart AO; Hansen R; Dubé L; Brooks DW
Ann N Y Acad Sci; 1994 Nov; 744():262-73. PubMed ID: 7825849
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW
J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186
[TBL] [Abstract][Full Text] [Related]
5. Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.
Bouska JJ; Bell RL; Goodfellow CL; Stewart AO; Brooks CD; Carter GW
Drug Metab Dispos; 1997 Sep; 25(9):1032-8. PubMed ID: 9311617
[TBL] [Abstract][Full Text] [Related]
6. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Bell RL; Bouska J; Young PR; Lanni C; Machinist J; Malo PE; Summers JB; Brooks DW; Carter GW
Agents Actions; 1993 Mar; 38(3-4):178-87. PubMed ID: 8213344
[TBL] [Abstract][Full Text] [Related]
7. Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
Satoh Y; Powers C; Toledo LM; Kowalski TJ; Peters PA; Kimble EF
J Med Chem; 1995 Jan; 38(1):68-75. PubMed ID: 7837242
[TBL] [Abstract][Full Text] [Related]
8. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW
Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602
[TBL] [Abstract][Full Text] [Related]
9. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.
Bell RL; Harris RR; Malo PE; Bouska JB; Shaughnessy TK; Hulkower KI; Brooks CD; Carter GW
J Pharmacol Exp Ther; 1997 Mar; 280(3):1366-73. PubMed ID: 9067325
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Wong SL; Drajesk J; Chang M; Lanni C; Witt G; Hansen R; Awni WM
Clin Pharmacol Ther; 1998 Mar; 63(3):324-31. PubMed ID: 9542476
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
Sweeny DJ; Nellans HN
Drug Metab Dispos; 1995 Jan; 23(1):149-53. PubMed ID: 7720519
[TBL] [Abstract][Full Text] [Related]
12. Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
Adams JL; Garigipati RS; Sorenson M; Schmidt SJ; Brian WR; Newton JF; Tyrrell KA; Garver E; Yodis LA; Chabot-Fletcher M; Tzimas M; Webb EF; Breton JJ; Griswold DE
J Med Chem; 1996 Dec; 39(26):5035-46. PubMed ID: 8978834
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
[TBL] [Abstract][Full Text] [Related]
14. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
[TBL] [Abstract][Full Text] [Related]
15. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
16. N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
Connolly PJ; Wetter SK; Beers KN; Hamel SC; Chen RH; Wachter MP; Ansell J; Singer MM; Steber M; Ritchie DM; Argentieri DC
Bioorg Med Chem Lett; 1999 Apr; 9(7):979-84. PubMed ID: 10230624
[TBL] [Abstract][Full Text] [Related]
17. Enantiomeric activation of glucuronidation in dog hepatic microsomes.
Sweeny DJ; Nellans HN
J Biol Chem; 1992 Jul; 267(19):13171-4. PubMed ID: 1618819
[TBL] [Abstract][Full Text] [Related]
18. Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with Dual 5-LO inhibitor and NO-dependent activities.
Boschi D; Giorgis M; Cena C; Talniya NC; Di Stilo A; Morini G; Coruzzi G; Guaita E; Fruttero R; Gasco A
ChemMedChem; 2010 Sep; 5(9):1444-9. PubMed ID: 20645382
[No Abstract] [Full Text] [Related]
19. A-78773: a selective, potent 5-lipoxygenase inhibitor.
Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
[TBL] [Abstract][Full Text] [Related]
20. 5-lipoxygenase inhibitory activity of zileuton.
Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
